In her 30 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US. Kate played an active role in setting up the Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.
Prior to joining SV, Kate worked for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.
In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine stepping down as Chair in December 2020. On December 8th 2020 the UK started COVID-19 vaccinations - the first Western country to do so. She was awarded a DBE in the Queen’s Birthday Honours in June 2021 for services to the procurement, manufacture and distribution of COVID-19 vaccines.
Outside of SV, Kate serves on the Board of the Francis Crick
Institute and won the Lifetime Achievement Award, presented by the BioIndustry
Association UK in January 2017. At weekends Kate spends time in Wales where she
rides horses and mountain bikes, grows vegetables and competes in bog
First class degree, Biochemistry, University of Oxford; MBA, Harvard Business School (Baker Scholar)